Mineralys Therapeutics, Inc.
MLYS
$14.25
$0.755.56%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -177.81M | -153.25M | -119.67M | -90.80M | -71.90M |
Total Depreciation and Amortization | 43.00K | 28.00K | 17.00K | 8.00K | -- |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 1.93M | -475.00K | -1.29M | -2.02M | -1.81M |
Change in Net Operating Assets | 9.52M | 25.25M | 23.64M | 5.27M | -7.47M |
Cash from Operations | -166.31M | -128.45M | -97.30M | -87.54M | -81.17M |
Capital Expenditure | -96.00K | -96.00K | -59.00K | -59.00K | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 115.06M | 23.40M | -52.24M | -76.11M | -160.47M |
Cash from Investing | 114.96M | 23.30M | -52.30M | -76.17M | -160.47M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 116.58M | 116.51M | 116.66M | 116.53M | 203.83M |
Repurchase of Common Stock | -- | -- | -- | -581.00K | -581.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -435.00K | -388.00K | -347.00K | -63.00K | -- |
Cash from Financing | 116.14M | 116.13M | 116.31M | 115.88M | 203.25M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 64.79M | 10.97M | -33.28M | -47.83M | -38.40M |